Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation

Search Page

Filters

My NCBI Filters

Results by year

Table representation of search results timeline featuring number of search results per year.

Year Number of Results
1974 1
1976 1
1977 2
1978 2
1979 5
1980 5
1981 9
1982 5
1983 6
1984 7
1985 9
1986 4
1987 8
1988 7
1989 8
1990 13
1991 10
1992 16
1993 10
1994 27
1995 22
1996 27
1997 41
1998 32
1999 47
2000 36
2001 47
2002 41
2003 50
2004 38
2005 35
2006 55
2007 67
2008 72
2009 78
2010 116
2011 119
2012 135
2013 115
2014 89
2015 91
2016 92
2017 76
2018 72
2019 84
2020 61
2021 37
2022 25
2023 21
2024 10

Text availability

Article attribute

Article type

Publication date

Search Results

1,796 results

Results by year

Filters applied: . Clear all
Page 1
Standard-dose versus high-dose conformal radiotherapy with concurrent and consolidation carboplatin plus paclitaxel with or without cetuximab for patients with stage IIIA or IIIB non-small-cell lung cancer (RTOG 0617): a randomised, two-by-two factorial phase 3 study.
Bradley JD, Paulus R, Komaki R, Masters G, Blumenschein G, Schild S, Bogart J, Hu C, Forster K, Magliocco A, Kavadi V, Garces YI, Narayan S, Iyengar P, Robinson C, Wynn RB, Koprowski C, Meng J, Beitler J, Gaur R, Curran W Jr, Choy H. Bradley JD, et al. Lancet Oncol. 2015 Feb;16(2):187-99. doi: 10.1016/S1470-2045(14)71207-0. Epub 2015 Jan 16. Lancet Oncol. 2015. PMID: 25601342 Free PMC article. Clinical Trial.
Rovalpituzumab tesirine, a DLL3-targeted antibody-drug conjugate, in recurrent small-cell lung cancer: a first-in-human, first-in-class, open-label, phase 1 study.
Rudin CM, Pietanza MC, Bauer TM, Ready N, Morgensztern D, Glisson BS, Byers LA, Johnson ML, Burris HA 3rd, Robert F, Han TH, Bheddah S, Theiss N, Watson S, Mathur D, Vennapusa B, Zayed H, Lally S, Strickland DK, Govindan R, Dylla SJ, Peng SL, Spigel DR; SCRX16-001 investigators. Rudin CM, et al. Lancet Oncol. 2017 Jan;18(1):42-51. doi: 10.1016/S1470-2045(16)30565-4. Epub 2016 Dec 5. Lancet Oncol. 2017. PMID: 27932068 Free PMC article. Clinical Trial.
Survival and prognosis of lung large cell neuroendocrine carcinoma.
Jiang H, Wu Q, Zhong Y. Jiang H, et al. Bull Cancer. 2021 Oct;108(10):981-987. doi: 10.1016/j.bulcan.2021.04.010. Epub 2021 Aug 12. Bull Cancer. 2021. PMID: 34392973
Relationships between clinical characteristics, diagnoses, treatment outcomes, and prognoses were retrospectively analyzed. RESULTS: Patients were followed for a median of 18.5 (0.5-41.0) months. ...DISCUSSION: Male patients with large cell neuroendocrine carcinoma with a …
Relationships between clinical characteristics, diagnoses, treatment outcomes, and prognoses were retrospectively analyzed. RESULTS: …
Dabrafenib plus trametinib in patients with previously treated BRAF(V600E)-mutant metastatic non-small cell lung cancer: an open-label, multicentre phase 2 trial.
Planchard D, Besse B, Groen HJM, Souquet PJ, Quoix E, Baik CS, Barlesi F, Kim TM, Mazieres J, Novello S, Rigas JR, Upalawanna A, D'Amelio AM Jr, Zhang P, Mookerjee B, Johnson BE. Planchard D, et al. Lancet Oncol. 2016 Jul;17(7):984-993. doi: 10.1016/S1470-2045(16)30146-2. Epub 2016 Jun 6. Lancet Oncol. 2016. PMID: 27283860 Free PMC article. Clinical Trial.
Bronchoesophageal Fistula.
di Mauro P, Ferrari V. di Mauro P, et al. N Engl J Med. 2020 Dec 17;383(25):e137. doi: 10.1056/NEJMicm2018535. N Engl J Med. 2020. PMID: 33326718 No abstract available.
Pulmonary large-cell neuroendocrine carcinoma (LCNEC).
Hage R, Seldenrijk K, de Bruin P, van Swieten H, van den Bosch J. Hage R, et al. Eur J Cardiothorac Surg. 2003 Apr;23(4):457-60. doi: 10.1016/s1010-7940(02)00837-0. Eur J Cardiothorac Surg. 2003. PMID: 12694759 Review.
CONCLUSIONS: LCNEC is a high-grade neuroendocrine tumor with a poor prognosis. In our patients, after surgical resection or multimodality treatment, all have developed widespread metastatic disease with a rapidly fatal course. Due to the rarity of this tumor, the in …
CONCLUSIONS: LCNEC is a high-grade neuroendocrine tumor with a poor prognosis. In our patients, after surgical resection or multimoda …
Large-cell neuroendocrine carcinoma of the lung.
Fernandez FG, Battafarano RJ. Fernandez FG, et al. Cancer Control. 2006 Oct;13(4):270-5. doi: 10.1177/107327480601300404. Cancer Control. 2006. PMID: 17075564 Free article. Review.
METHODS: The initial evaluation and diagnosis, tumor classification, surgical treatment, results of therapy, and long-term prognosis of patients with LCNEC based on our experience are discussed, and a review of the literature is presented. ...
METHODS: The initial evaluation and diagnosis, tumor classification, surgical treatment, results of therapy, and long-term prognosis …
Large-Cell Neuroendocrine Carcinoma of the Lung: A Population-Based Study.
Kinslow CJ, May MS, Saqi A, Shu CA, Chaudhary KR, Wang TJC, Cheng SK. Kinslow CJ, et al. Clin Lung Cancer. 2020 Mar;21(2):e99-e113. doi: 10.1016/j.cllc.2019.07.011. Epub 2019 Aug 3. Clin Lung Cancer. 2020. PMID: 31601526
Despite this, it remains poorly studied and did not demonstrate an improved prognosis in our cohort....
Despite this, it remains poorly studied and did not demonstrate an improved prognosis in our cohort....
1,796 results